Nav: Home

Scripps research scientists develop a new strategy to fight obesity

October 27, 2008

The antibody works against the gastric hormone ghrelin (pronounced "grell-in"), which has been linked to weight gain and fat storage through its metabolic actions. These findings point towards a potentially novel treatment for obesity that would interfere directly with the some of the biological mechanisms determining weight.

The study is being published the week of October 27, 2008, in an advance, online Early Edition of the journal Proceedings of the National Academy of Sciences (PNAS).

In the study, which was led by investigators Kim Janda and Eric P. Zorrilla of The Scripps Research, the antibody catalyst GHR-11E11 led to a higher metabolic rate in fasting mice and suppressed feeding following 24-hour food deprivation.

"Our study showed that this novel catalytic ghrelin antibody could specifically seek out and degrade ghrelin," said Janda, who is Ely R. Callaway, Jr. Professor of Chemistry, member of The Skaggs Institute for Chemical Biology, and director, Worm Institute of Research and Medicine (WIRM), at Scripps Research. "While this antibody lacks a high level of catalytic efficiency, our study clearly demonstrates that even a basal level of catalysis can effectively modulate feeding behavior. These findings not only validate antibody-based therapeutics, but strongly suggest that catalytic anti-ghrelin antibodies might help patients reach and maintain their weight loss goals."

According to recent reports from the World Health Organization, about 1 billion people worldwide are overweight or obese, with most of these in the developed world. In the United States, for example, the National Health and Nutrition Examination Survey found that, in 2003-2004, approximately 66 percent of all adults 20 years of age or older were overweight or obese. Almost four out of every five American men aged 40 to 59 were classified as overweight, according to a 2006 study published by the Journal of the American Medical Association.

Targeting Ghrelin

While non-surgical treatments can be modestly effective against obesity, weight loss or gain can be affected by ghrelin, which is released by the body to encourage eating during periods of calorie restriction. A gastric endocrine hormone produced primarily in the stomach, ghrelin promotes weight gain and fat storage through its metabolic actions, decreasing the break down of stored fat for energy as well as energy expenditure itself.

During periods of weight loss, the body produces high levels of ghrelin to encourage eating. Human studies have shown that ghrelin levels rise before meals and fall afterwards, findings that are consistent with the hormone's role in hunger and eating initiation. Indeed, circulating ghrelin levels are increased by food deprivation and decreased by eating, glucose load, insulin, and somatostatin, an important neural signaling hormone. Recent studies suggest mice deficient for ghrelin or its receptor store less of their consumed food and are resistant to diet-induced obesity. Also, small-molecule ghrelin receptor antagonists have been shown to reduce food intake, promote selective weight loss in the form of body fat, and improve glucose tolerance by augmenting glucose-induced insulin secretion.

The new study suggests the possibility that passive immunopharmacotherapy with a catalytic anti-ghrelin antibody such as GHR-11E11 could decrease the level of serum ghrelin as well as modulate energy homeostasis.

"The reason we looked at passive immunopharmacotherapy to treat obesity was because agonist/antagonist types of drugs have been remarkably unsuccessful," Janda said. "They are effective only while treatment is maintained and when treatment stops, weight returns. For obesity treatments to work, they must affect food intake and energy expenditure or storage--which is what this new catalytic antibody does by degrading ghrelin. Some people have the idea that because ghrelin is an endogenous hormone there might be too many adverse side effects if you eliminate it, but there is new evidence that the body itself produces antibodies against ghrelin."

Immunotherapeutic approaches against ghrelin may hold certain advantages over small-molecule antagonist treatments. First, immunoneutralization would occur outside the central nervous system, eliminating potential side effects that might occur with blood-brain barrier-penetrating small molecule antagonists. Second, therapeutic antibodies utilize the bloodstream as a site of action, which produces a pharmacological profile of safety and efficacy that is highly predictable and reproducible. In addition, immunization against a ligand may be more effective than small molecule receptor antagonist approaches when the receptor targets are unknown, multiple, or difficult to bind with any specificity.

Given the complex nature of obesity, any antibody-based strategy would most likely be used in combination with other available drugs, and as part of a comprehensive treatment approach that included nutritional, exercise, educational, and psychosocial components, Janda said.

However, he added, more research is needed. In addition to the development of more effective ghrelin antibodies, scientists need to better understand issues such as the effect of the antibodies over the long-term and their impact on individuals with varying body weights.
-end-
The first author of the study, Catalytic Antibody Degradation of Ghrelin Increases Whole-Body Metabolic Rate and Reduces Refeeding in Fasting Mice, is Alexander V. Mayorov of The Scripps Research Institute and The Skaggs Institute for Chemical Biology. In addition to Janda, Zorrilla, and Meijler, other authors include Jason Y. Chang, Jason A. Moss, Mark S. Hixon and Diana I. Ruiz of The Scripps Research Institute and The Skaggs Institute for Chemical Biology and Neri Amara of Ben-Gurion University of the Negev, Israel. The study was supported in part by the National Institutes of Health, the McDonald's Center for Type 2 Diabetes and Obesity, The Skaggs Institute for Chemical Biology, and the Rich Initiative for Excellence in the Negev.

About The Scripps Research Institute

The Scripps Research Institute is one of the world's largest independent, non-profit biomedical research organizations, at the forefront of basic biomedical science that seeks to comprehend the most fundamental processes of life. Scripps Research is internationally recognized for its discoveries in immunology, molecular and cellular biology, chemistry, neurosciences, autoimmune, cardiovascular, and infectious diseases, and synthetic vaccine development. Established in its current configuration in 1961, it employs approximately 3,000 scientists, postdoctoral fellows, scientific and other technicians, doctoral degree graduate students, and administrative and technical support personnel. Scripps Research is headquartered in La Jolla, California. It also includes Scripps Florida, whose researchers focus on basic biomedical science, drug discovery, and technology development. Currently operating from temporary facilities in Jupiter, Scripps Florida will move to its permanent campus by 2009.

Scripps Research Institute

Related Obesity Articles:

Changing the debate around obesity
The UK's National Health Service (NHS) needs to do more to address the ingrained stigma and discrimination faced by people with obesity, says a leading health psychologist.
Study links longer exposure to obesity and earlier development of obesity to increased risk of type 2 diabetes
Cumulative exposure to obesity could be at least as important as actually being obese in terms of risk of developing type 2 diabetes (T2D), concludes new research published in Diabetologia (the journal of the European Association for the Study of Diabetes [EASD]).
How much do obesity and addictions overlap?
A large analysis of personality studies has found that people with obesity behave somewhat like people with addictions to alcohol or drugs.
Should obesity be recognized as a disease?
With obesity now affecting almost a third (29%) of the population in England, and expected to rise to 35% by 2030, should we now recognize it as a disease?
Is obesity associated with risk of pediatric MS?
A single-center study of 453 children in Germany with multiple sclerosis (MS) investigated the association of obesity with pediatric MS risk and with the response of first-line therapy in children with MS.
Women with obesity prior to conception are more likely to have children with obesity
A systematic review and meta-analysis identified significantly increased odds of child obesity when mothers have obesity before conception, according to a study published June 11, 2019 in the open-access journal PLOS Medicine by Nicola Heslehurst of Newcastle University in the UK, and colleagues.
Obesity medicine association announces major updates to its adult obesity algorithm
The Obesity Medicine Association (OMA) announced the immediate availability of the 2019 OMA Adult Obesity Algorithm, with new information for clinicians including the relationship between Obesity and Cardiovascular Disease, Diabetes Mellitus, Dyslipidemia, and Cancer; information on investigational Anti-Obesity Pharmacotherapy; treatments for Lipodystrophy; and Pharmacokinetics and Obesity.
Systematic review shows risk of a child developing overweight or obesity is more than trebled by maternal obesity prior to pregnancy
New research presented at this year's European Congress on Obesity (ECO) in Glasgow, Scotland (April 28- May 1) reveals that the risk of a child becoming overweight or obese is more than trebled by maternal obesity prior to getting pregnant.
Eating later in the day may be associated with obesity
Eating later in the day may contribute to weight gain, according to a new study to be presented Saturday at ENDO 2019, the Endocrine Society's annual meeting in New Orleans, La.
How obesity affects vitamin D metabolism
A new Journal of Bone and Mineral Research study confirms that vitamin D supplementation is less effective in the presence of obesity, and it uncovers a biological mechanism to explain this observation.
More Obesity News and Obesity Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Processing The Pandemic
Between the pandemic and America's reckoning with racism and police brutality, many of us are anxious, angry, and depressed. This hour, TED Fellow and writer Laurel Braitman helps us process it all.
Now Playing: Science for the People

#568 Poker Face Psychology
Anyone who's seen pop culture depictions of poker might think statistics and math is the only way to get ahead. But no, there's psychology too. Author Maria Konnikova took her Ph.D. in psychology to the poker table, and turned out to be good. So good, she went pro in poker, and learned all about her own biases on the way. We're talking about her new book "The Biggest Bluff: How I Learned to Pay Attention, Master Myself, and Win".
Now Playing: Radiolab

Invisible Allies
As scientists have been scrambling to find new and better ways to treat covid-19, they've come across some unexpected allies. Invisible and primordial, these protectors have been with us all along. And they just might help us to better weather this viral storm. To kick things off, we travel through time from a homeless shelter to a military hospital, pondering the pandemic-fighting power of the sun. And then, we dive deep into the periodic table to look at how a simple element might actually be a microbe's biggest foe. This episode was reported by Simon Adler and Molly Webster, and produced by Annie McEwen and Pat Walters. Support Radiolab today at Radiolab.org/donate.